Figure 1.
Kaplan–Meier estimates for 92 patients with advanced esophageal squamous cell carcinoma treated with an immune checkpoint inhibitor (ICI)-based therapy. (A) Progression-free survival (PFS) and (B) overall survival (OS) in ICI + chemotherapy (chemo). (C) PFS and (D) OS in nivolumab + ipilimumab (nivo + ipi). CI, confidence interval; NR; not reached.
